Evidence supporting the use of: Flavonols
For the health condition: Cirrhosis of the Liver

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Flavonols, a class of flavonoids found in many fruits and vegetables (notably quercetin, kaempferol, and myricetin), have attracted scientific interest for their antioxidant and anti-inflammatory properties. Preclinical (animal and cell culture) studies suggest that flavonols may help mitigate liver injury by reducing oxidative stress, inhibiting inflammation, and modulating fibrogenic pathways implicated in cirrhosis development. For example, quercetin has been shown to decrease hepatic stellate cell activation and collagen deposition in animal models of liver fibrosis, which is a key process in cirrhosis progression. Some studies also report reduced markers of liver damage (such as ALT and AST) and improved liver histology in rodents treated with flavonols or flavonol-rich extracts.

However, there is a lack of robust human clinical trials confirming these effects in patients with established cirrhosis. Most available human data are limited to observational or small pilot studies, often involving mixed flavonoid supplements rather than purified flavonols. While the preclinical evidence is promising and forms a scientific rationale for further investigation, the current level of clinical evidence supporting flavonols as a treatment or supportive therapy for cirrhosis is low. Therefore, their use should be considered experimental and adjunctive, rather than a primary therapeutic option.

In summary, there is some scientific basis (from laboratory and animal studies) for the potential role of flavonols in liver health and fibrosis reduction, but little direct clinical evidence to support their use specifically for cirrhosis in humans.

More about flavonols
More about Cirrhosis of the Liver